HTG will leverage existing collaborations with firms including Illumina and Thermo Fisher Scientific tocontinue building in vitro diagnostic assays on their sequencers.
Qiagen, which is also developing a single-plex qRT-PCR assay for 2019-nCoV, said it will have a syndromic panel including targets for the virus ready this month.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.
The firm had received interest from unnamed potential acquisition partners following the departure of its CEO, but it has decided to remain as a standalone business.
